Kemshead J T, Hancock J, Liberti P
Imperial Cancer Research Fund, Paediatric and Neuro-Oncology Group, Frenchay Hospital, Bristol, U.K.
J Hematother. 1994 Spring;3(1):51-7. doi: 10.1089/scd.1.1994.3.51.
The characterization of tumor cells in bone marrow harvested for autologous bone marrow rescue remains a problem due to the limited sensitivities of the techniques available for their analysis. This complicates the use of purging techniques as their usefulness is debated, specifically because it is not known if they can remove all residual tumor cells from either peripheral blood stem cell harvests or bone marrow. Apart from developing more sensitive techniques for tumor detection, one way of increasing our efficiency at identifying rare malignant cells in normal hematopoietic cells is to develop approaches to enrich the population of interest prior to analysis. Here, we describe a laboratory-based system for tumour enrichment employing panels of monoclonal antibodies (MAbs) and an immunomagnetic colloid. In model systems, tumor cells could be enriched approximately 100-fold with high yield and purity. The adaptations of this technology to permit further cell enrichment and the choice of either an immunological technique or a molecular approach to tumor identification are discussed in detail.
由于用于分析的现有技术灵敏度有限，为自体骨髓救援采集的骨髓中肿瘤细胞的表征仍然是一个问题。这使得净化技术的使用变得复杂，因为其有效性存在争议，特别是因为尚不清楚它们是否能从外周血干细胞采集物或骨髓中清除所有残留肿瘤细胞。除了开发更灵敏的肿瘤检测技术外，提高我们在正常造血细胞中识别罕见恶性细胞效率的一种方法是在分析之前开发富集目标群体的方法。在此，我们描述了一种基于实验室的肿瘤富集系统，该系统使用单克隆抗体（MAb）组合和免疫磁胶体。在模型系统中，肿瘤细胞可以以高产率和高纯度富集约100倍。详细讨论了对该技术进行调整以实现进一步的细胞富集，以及选择免疫技术或分子方法进行肿瘤鉴定的问题。
